Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study.

Autor: Sanz Segura P; Gastroenterology Department, Hospital Royo Villanova, Zaragoza, Spain. Electronic address: patricia.sanz.segura@gmail.com., Gomollón F; Gastroenterology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Instituto de Investigación Sanitaria (ISS) Aragón, Zaragoza, Spain., Casas D; Instituto de Investigación Sanitaria (ISS) Aragón, Zaragoza, Spain; Gastroenterology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain., Iborra M; Gastroenterology Department, Hospital Universitario La Fe, Valencia, Spain., Vela M; Gastroenterology Department, Hospital Universitario Ntra. Sra. de Candelaria, Santa Cruz de Tenerife, Spain., Fernández-Clotet A; Gastroenterology Department, Hospital Clinic de Barcelona. Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd). Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Muñoz R; Gastroenterology Department, Hospital General Universitario Dr. Balmis, Alicante, Spain., García de la Filia I; Gastroenterology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., García Prada M; Gastroenterology Department, Complejo Asistencial Universitario de León, Spain., Ferrer Rosique JÁ; Gastroenterology Department, Hospital Fundación Alcorcón, Madrid, Spain., García MJ; Gastroenterology and Hepatology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain., de Francisco R; Gastroenterology Department, Hospital Universitario Central de Asturias, and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain., Arias L; Gastroenterology Department, Hospital Universitario de Burgos, Burgos, Spain., Barrio J; Gastroenterology Department, Hospital Universitario Río Hortega. Gerencia Regional de Salud de Castilla y León (SACYL). Valladolid, Spain., Guerra I; Gastroenterology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain., Ponferrada Á; Gastroenterology Department, Hospital Universitario Infanta Leonor, Madrid, Spain., Gisbert JP; Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain., Carrillo-Palau M; Gastroenterology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain., Calvet X; Servei d'Aparell Digestiu. Parc Taulí, Hospital Universitari. Institutd'Investigació i Innovació Parc Taulí(I3PT-CERCA). Universitat Autònoma de Barcelona. Sabadell, Spain. Centro de Investigación Biomédica En Red de enfermedades hepáticas y digestivas (CIBERehd). Instituto de Salud Carlos III. Madrid, Spain., Márquez-Mosquera L; Servei de Digestiu, Hospital del Mar, Barcelona, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain., Gros B; Gastroenterology Department, Hospital Universitario Reina Sofía, Córdoba, Spain., Cañete F; Gastroenterology Department, Hospital Universitari Germans Trials i Pujol and CIBERehd, Badalona, Barcelona, Spain., Monfort D; Gastroenterology Department, Consorci Sanitari de Terrassa, Spain., Madrigal Domínguez RE; Gastroenterology Department, Hospital Clínico Universitario de Valladolid, Spain., Roncero Ó; Gastroenterology Department, Hospital General La Mancha Centro, Ciudad Real, Spain., Laredo V; Gastroenterology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain., Montoro M; Gastroenterology Department, Hospital San Jorge, Huesca, Spain., Muñoz C; Gastroenterology Department, Hospital de Basurto, Bilbao, Spain., López-Cauce B; Gastroenterology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Lorente R; Gastroenterology Department, Hospital General de Ciudad Real, Ciudad Real, Spain., Fuentes Coronel A; Gastroenterology Department, Hospital Virgen de La Concha, Complejo Asistencial de Zamora, Zamora, Spain., Vega P; Gastroenterology Department, Complejo Hospitalario Universitario de Ourense, Ourense, Spain., Martín D; Gastroenterology Department, Hospital Universitario La Paz, Madrid, Spain., Peña E; Gastroenterology Department, Hospital Royo Villanova, Zaragoza, Spain., Varela P; Gastroenterology Department, Hospital Universitario de Cabueñes, Gijón, Spain., Olivares S; Gastroenterology Department, Hospital 12 de Octubre, Madrid, Spain., Pajares R; Gastroenterology Department, Hospital Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain., Lucendo AJ; Gastroenterology Department, Hospital General de Tomelloso, IIS-IP, Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM) and CIBEREHD Ciudad Real, Spain., Sesé E; Gastroenterology Department, Hospital Universitario Arnau de Vilanova de Lleida, Spain., Botella Mateu B; Gastroenterology Department, Hospital Universitario Infanta Cristina, Madrid, Spain., Nos P; Gastroenterology Department, Hospital Universitario La Fe, Valencia, Spain., Domènech E; Gastroenterology Department, Hospital Universitari Germans Trials i Pujol and CIBERehd, Badalona, Barcelona, Spain., García-López S; Gastroenterology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Jazyk: angličtina
Zdroj: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2024 Jun 13. Date of Electronic Publication: 2024 Jun 13.
DOI: 10.1016/j.dld.2024.05.021
Abstrakt: Background: some patients with inflammatory bowel disease (IBD) treated with antiTNF develop drug-induced psoriasis (antiTNF-IP). Several therapeutic strategies are possible.
Aims: to assess the management of antiTNF-IP in IBD, and its impact in both diseases.
Methods: patients with antiTNF-IP from ENEIDA registry were included. Therapeutic strategy was classified as continuing the same antiTNF, stopping antiTNF, switch to another antiTNF or swap to a non-antiTNF biologic. IP severity and IBD activity were assessed at baseline and 16, 32 and 54 weeks.
Results: 234 patients were included. At baseline, antiTNF-IP was moderate-severe in 60 % of them, and IBD was in remission in 80 %. Therapeutic strategy was associated to antiTNF-IP severity (p < 0.001). AntiTNF-IP improved at week 54 with all strategies, but continuing with the same antiTNF showed the worst results (p = 0.042). Among patients with IBD in remission, relapse was higher in those who stopped antiTNF (p = 0.025). In multivariate analysis, stopping antiTNF, trunk and palms and soles location were associated with antiTNF-IP remission; female sex and previous surgery in Crohn´s disease with IBD relapse.
Conclusion: skin lesions severity and IBD activity seem to determine antiTNF-IP management. Continuing antiTNF in mild antiTNF-IP, and swap to ustekinumab or switch to another antiTNF in moderate-severe cases, are suitable strategies.
Competing Interests: Conflict of interest DCD is partially supported by a Rio-Hortega fellowship from Instituto de Salud Carlos III. IM reports grants and personal fees from MSD, Janssen, Takeda, Kern and Chiesi, during the conduct of the study. AFC has served as a speaker, or has received education funding from Dr. Falk, Janssen, Takeda, Chiesi and Pfizer. MJG has received financial support for travelling and educational activities from Janssen, Pfizer, AbbVie, Takeda, Kern Pharma, Faes Farma and Ferring. IG has served as speaker or has received education funding from Takeda and Tillots. JPG has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos, Lilly, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine and Vifor Pharma. XC reports grants or contracts from Abbvie, Janssen, Kern, Takeda, Galapagos, Lilly, Sandoz; consulting fees from Janssen; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie, Janssen, Takeda, Galapagos, Kern; participation on a Data Safety Monitoring Board or Advisory Board: X Jansen, Galapagos; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Past-president, Societat Catalana de Digestologia. BG has served as advisor to Galapagos and Abbvie and as speaker for Abbvie, Jansen, Takeda, Pfizer and Galapagos. REM reports grants and personal fees from Janssen, Pfizer and Ferring. NP has served as speaker, consultant and advisory board of has received research funding from MSD, Abbvie, Janssen, Takeda, Roche, Sandoz, Ferring, Adacyte, Faes Farma, Kern Pharma, Pfizer, Shire Pharmaceuticals, Vifor Pharma, Chiesi and Tillots. SGL has served as a speaker, advisory member for or has received research funding from AbbVie, MSD, Takeda, Janssen and Pfizer.
(Copyright © 2024 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: